Exploring the biological behavior and underlying mechanism of KITLG in triple-negative breast cancer
Related Experiment Video
Updated: Jul 5, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Liuqing Qin1, Yuchao Li1, Yifei Huang1
1Department of Gastrointestinal Gland Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China.
Abstract:
The tyrosine-kinase receptor that is specified by the KIT locus is demarcated by KITLG. This multifaceted factor is instrumental during in-utero germ and neural cell maturation and hematopoiesis, ostensibly reflecting its role in facilitating cell migration. Concurrently, KITLG is prone to a mutation in germ cell tumors, entailing a presumed connection to tumorigenesis. Despite this, the intricacies of its function in breast cancer and the relevant mechanisms remain elusive. Multiple independent databases depict a consistently low expression of KITLG within tissues affected by triple-negative breast cancers (TNBC), a trend strongly coupled with reduced survival rates. Interestingly, non-triple-negative breast cancers exhibit a markedly high expression of KITLG compared to the norm. An initial analysis of the GEO database speculates that KITLG may serve as an oncogene suppressor in TNBC, hinting at varied roles for KITLG isoforms within this disease context. In conclusion, our preliminary analysis offers valuable insights into the role and expression pattern of KITLG in TNBC. We provide evidence supporting its consideration as a promising new prognostic marker, thereby potentially enriching therapeutic strategies for TNBC. Indeed, given the limited advances in molecularly targeted therapy for TNBC, a significant need exists for a more precise therapeutic approach and a comprehensive understanding of its inherent mechanisms of action.
Insights
KITLG, a factor crucial for cell development, shows low expression in triple-negative breast cancer (TNBC), correlating with poor survival. This suggests KITLG may suppress tumors, offering a potential new prognostic marker for TNBC.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- KITLG (KIT ligand) is a factor involved in cell development, migration, and hematopoiesis.
- KITLG mutations are linked to germ cell tumors, but its role in breast cancer is unclear.
- Triple-negative breast cancer (TNBC) has limited targeted therapy options.
Purpose of the Study:
- To investigate the role and expression patterns of KITLG in breast cancer, particularly TNBC.
- To explore KITLG as a potential prognostic marker and therapeutic target for TNBC.
Main Methods:
- Analysis of gene expression data from multiple independent databases, including the GEO database.
- Correlation analysis between KITLG expression levels and patient survival rates in TNBC and non-TNBC tissues.
Main Results:
- Consistently low KITLG expression was observed in TNBC tissues, associated with reduced survival rates.
- Non-TNBC tissues exhibited significantly higher KITLG expression compared to normal tissues.
- Preliminary analysis suggests KITLG may function as an oncogene suppressor in TNBC.
Conclusions:
- KITLG expression patterns differ significantly between TNBC and non-TNBC.
- KITLG shows promise as a novel prognostic marker for TNBC.
- Further research into KITLG's mechanisms could inform new therapeutic strategies for TNBC.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway

